Suppr超能文献

普瑞巴林治疗伴有下肢疼痛(神经病理性成分)的慢性下腰痛的有效性:日本的一项非干预性研究。

Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan.

作者信息

Taguchi Toshihiko, Igarashi Ataru, Watt Stephen, Parsons Bruce, Sadosky Alesia, Nozawa Kazutaka, Hayakawa Kazuhiro, Yoshiyama Tamotsu, Ebata Nozomi, Fujii Koichi

机构信息

Department of Orthopaedic Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.

Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

出版信息

J Pain Res. 2015 Aug 5;8:487-97. doi: 10.2147/JPR.S88642. eCollection 2015.

Abstract

OBJECTIVE

To evaluate the impact of pregabalin on sleep, pain, function, and health status in patients with chronic low back pain with accompanying neuropathic pain (CLBP-NeP) under routine clinical practice.

METHODS

This prospective, non-interventional, observational study enrolled Japanese adults (≥18 years) with CLBP-NeP of duration ≥3 months and severity ≥5 on a numerical rating scale (0= no pain, 10= worst possible pain). Treatment was 8 weeks with pregabalin (n=157) or usual care alone (n=174); choice of treatment was determined by the physician. The primary efficacy outcome was change from baseline to 8 weeks in pain-related interference with sleep, assessed using the Pain-Related Sleep Interference Scale (PRSIS; 0= did not interfere with sleep, 10= completely interferes with sleep). Secondary endpoints were changes in PRSIS at week 4, and changes at weeks 4 and 8 in pain (numerical rating scale), function (Roland-Morris Disability Questionnaire), and quality of life (EuroQol 5D-5L); global assessments of change were evaluated from the clinician and patient perspectives at the final visit.

RESULTS

Demographic characteristics were similar between cohorts, but clinical characteristics suggested greater disease severity in the pregabalin group including a higher mean (standard deviation) pain score, 6.3 (1.2) versus 5.8 (1.1) (P<0.001). For the primary endpoint, pregabalin resulted in significantly greater improvements in PRSIS at week 8, least-squares mean changes of -1.3 versus -0.4 for usual care (P<0.001); pregabalin also resulted in greater PRSIS improvement at week 4 (P=0.012). Relative to usual care at week 8, pregabalin improved pain and function (both P<0.001), and showed global improvements since beginning study medication (P<0.001). Pregabalin was well tolerated.

CONCLUSION

In clinical practice in patients with CLBP-NeP, pregabalin showed significantly greater improvements in pain-related interference with sleep relative to usual care. In addition, pregabalin significantly improved pain, function, and health status, suggesting the benefits of pregabalin for overall health and well-being relative to usual care in these patients. (Clinicaltrials. gov identifier NCT02273908).

摘要

目的

在常规临床实践中,评估普瑞巴林对伴有神经性疼痛的慢性下腰痛(CLBP-NeP)患者的睡眠、疼痛、功能及健康状况的影响。

方法

本前瞻性、非干预性观察性研究纳入了病程≥3个月且数字评定量表(0=无疼痛,10=可能的最严重疼痛)评分≥5的日本成年(≥18岁)CLBP-NeP患者。治疗为期8周,其中157例患者使用普瑞巴林,174例患者仅接受常规护理;治疗选择由医生决定。主要疗效指标是使用疼痛相关睡眠干扰量表(PRSIS;0=未干扰睡眠,10=完全干扰睡眠)评估从基线到8周疼痛对睡眠的干扰变化。次要终点为第4周时PRSIS的变化,以及第4周和第8周时疼痛(数字评定量表)、功能(罗兰·莫里斯残疾问卷)和生活质量(欧洲五维健康量表5D-5L)的变化;在末次访视时从临床医生和患者的角度评估整体变化情况。

结果

两组人群的人口统计学特征相似,但临床特征表明普瑞巴林组疾病严重程度更高,包括更高的平均(标准差)疼痛评分,分别为6.3(1.2)和5.8(1.1)(P<0.001)。对于主要终点,普瑞巴林在第8周时使PRSIS有显著更大改善,最小二乘均值变化为-1.3,而常规护理为-0.4(P<0.001);普瑞巴林在第4周时也使PRSIS有更大改善(P=0.012)。相对于第8周的常规护理,普瑞巴林改善了疼痛和功能(均P<0.001),且自开始研究用药以来显示出整体改善(P<0.001)。普瑞巴林耐受性良好。

结论

在CLBP-NeP患者的临床实践中,相对于常规护理,普瑞巴林在疼痛对睡眠的干扰方面显示出显著更大的改善。此外,普瑞巴林显著改善了疼痛、功能和健康状况,表明相对于常规护理,普瑞巴林对这些患者的整体健康和幸福感有益。(Clinicaltrials.gov标识符NCT02273908)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c56/4531006/80367b94037d/jpr-8-487Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验